期刊文献+

丹参酮ⅡA抑制肾性高血压大鼠氧化应激和心肌肥厚 被引量:16

Tanshinone Ⅱ A Attenuated Oxidative Stress and Left Ventricular Hypertrophy Induced by Renovascular Hypertension
原文传递
导出
摘要 背景血管还原型烟酰胺腺嘌呤二核苷酸(磷酸)[NAD(P)H]氧化酶激活产生的活性氧增多所产生的氧化损伤在左心室肥厚的发生发展中起重要作用,丹参酮ⅡA被证实能通过抗氧化作用阻滞粥样硬化斑块的发展,但它对左心室肥厚的发生发展有无影响尚未见实验证实。目的观察丹参酮ⅡA(TanⅡA)对两肾两夹手术造成的肾性高血压大鼠左心室肥厚的作用,并与缬沙坦的作用相比较,探讨TanⅡA防治心室肥厚的作用机制。方法实验分5组:对照组、模型组、缬沙坦组[30 mg/(kg.d)]、TanⅡA高剂量组[TanH,70 mg/(kg.d)]和TanⅡA低剂量组[TanL,35 mg/(kg.d)]。术后4周开始药物处理,连续给药6周,测定血压和左室质量指数,行超声心动图检查,采用共聚焦显微镜检测左心室和主动脉中O2.-的产生情况,用化学发光仪测定NAD(P)H氧化酶的活性。结果两肾两夹大鼠手术后4周血压升至180 mm Hg左右,显著高于对照组(P<0.05),模型组大鼠术后10周,左心室肥厚较对照组明显(P<0.05),心肌和主动脉壁中O2.-的产生明显增多(P<0.01),NAD(P)H氧化酶活性明显升高(P<0.05);TanⅡA治疗高血压大鼠6周后显著抑制左心室肥厚的发展(P<0.05),明显减少心肌和主动脉中的O2.-产生(P<0.05),降低NAD(P)H氧化酶活性(P<0.05),高剂量作用显著,但未见明显降低血压作用;缬沙坦不但能减轻氧化应激和心室肥厚发展,还能明显降低血压(均P<0.05)。结论丹参酮ⅡA抑制心肌肥厚的作用可能与降低NAD(P)H氧化酶活性从而减少O2.-的产生有关。 Background There is increasing evidence that oxidative stress,overproduction of reactive oxygen species(ROS) originating from nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase,plays a critical role in the development and progression of cardiac remodeling associated with heart failure.Many experimental and clinical studies have reported that tanshinone ⅡA(TanⅡA) is an anti-oxidant effective for inibition of atherosclerosis.However,no studies have addressed the effect of TanⅡA on cardiac hypertrophy.Objective To study the effects of TanⅡA on left ventricular hypertrophy induced by renovascular hypertension after two-kidney two-clip(2K2C) operation,and the impossible underlying mechanism.Methods There were 5 groups in the experiment: control: rats received sham operation and given 0.5% carboxymethylcellulose sodium;2K2C: rats received 2K2C operation and given 0.5% carboxymethylcellulose sodium;valsartan: 2K2C rats given valsartan [30 mg/(kg·d)];TanH: 2K2C rats given TanⅡA [70 mg/(kg·d)] and TanL: 2K2C rats given TanⅡA [35 mg/(kg·d)].At the endpoint of the experiment,echocardiography was performed.Then the rats were sacrificed,body mass(BM) and left ventricule mass(LVM) were determined,and the LVMI was calculated.The oxidative fluorescence dye dihydroethidium detected by laser confocal fluorescent microscopy was used to evaluate in situ O2.-generation in the LV and aorta.The NAD(P)H oxidase activity in LV and aorta was estimated with lucigenin-enhanced chemiluminescence.Results Compared with the control rats,BP of 2K2C rats was elevated to about 180 mm Hg at week 4 after operation(P0.05).Ten weeks after operation,2K2C rats developed obvious LV hypertrophy,with enhanced O2.-generation and NAD(P)H oxidase activity in LV and aorta(P0.05).Tan ⅡA,more significantly in high dose,attenuated LVH(P0.05) and reversed the over oxidative stress by inhibiting generation of O2.-(P0.01)and the activation of NAD(P)H oxidase(P0.05) in LV and aorta after treatment for 6 weeks though BP wasnot decreased significantly,while valsartan,not only attenuated LVH and oxidative stress,but also decreased BP markedly.Conclusion Tan ⅡA significantly reverse the LV hypertrophy in 2K2C rats,that might be associated with attenuation of NAD(P)H oxidase-derived reactive oxygen species production.
出处 《中华高血压杂志》 CAS CSCD 北大核心 2010年第3期229-234,共6页 Chinese Journal of Hypertension
基金 国家自然科学基金资助项目(30472022) 广东省关键领域重大突破招标项目(2003A30904)
关键词 丹参酮ⅡA 左心室肥厚 活性氧簇 还原型烟酰胺腺嘌呤二核苷酸(磷酸)氧化酶 Tanshinone ⅡA Left ventricular hypertrophy Reactive oxygen species Nicotinamide adenine dinucleotide phosphate oxidase
  • 相关文献

参考文献14

  • 1卢永昕.高血压:从左室肥厚到心力衰竭[J].中华高血压杂志,2007,15(3):189-191. 被引量:49
  • 2Zhou G, Jiang W, Zhao Y, et al. Sodium tanshinone II A sulfonate mediates transfer reaction in rat heart mitochondria[J]. Bioehem Pharmacol, 2003,65 ( 1 ) : 51-57.
  • 3李永胜,王照华,严丽,雍永权,王进,梁黔生,郑智,杨光田.丹参酮Ⅱ A对左心室肥厚的逆转作用及其机制[J].中华高血压杂志,2007,15(11):900-903. 被引量:16
  • 4Zhou SG, Zhou SF, Huang HQ, etal. Proteomie analysis of hypertrophied myocardial protein patterns in renovaseular hypertensive and spontaneously hypertensive rats[J]. J Proteome Res, 2006,5(11) :2901-2908.
  • 5Bishop JE, Kieman LA, Montgomery HE, et al. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2) 27 rats[J]. Cardiovasc Res,2000,47(1) :57-67.
  • 6Nakamura Y, YoshiyamaM, Omura T, et al. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction[J]. Cardiovasc Res,2003,57(1) :48-54.
  • 7EjiriJ, Inoue N, Tsukube T, etal. Oxidative stressin the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin Ⅱ type 1 receptor blocker[J]. Cardiovasc Res,2003, 59(4):988-996.
  • 8Jalil JE, Perez A, Ocaranza MP, et al. Increased aortic NADPH oxidase activity in rats with genetically high angiotensin-converring enzyme levels[J]. Hypertension,2005,46(6) :1362-1367.
  • 9Akki A, Zhang M, Murdoch C, et al. NADPH oxidase signaling and cardiac myocyte function[J]. J Mol Cell Cardiol, 2009,47( 1):15-22.
  • 10Yokoyama H, Averill DB, Brosnihan KB, et al. Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy[J].AmJ Hypertens,2005,18(7):922-929.

二级参考文献21

  • 1姜志胜.心肌肥大过程中的信号转导[J].中国动脉硬化杂志,2005,13(2):125-128. 被引量:20
  • 2钟南田,符史干,符皎荣,林世珍,洪灯,郑小桃.一氧化氮在压力超负荷心肌肥大作用中的定量分析[J].解剖学杂志,2005,28(5):517-519. 被引量:8
  • 3[1]Alan H,Fadi A.From left ventricular hypertrophy to congestive heart failure:management of hypertensive heart disease[J].Progress in Cardiovascular Disease,2006,48,326-341.
  • 4[2]Kiyoshi M,Koji F,Hideyuki O,et al.Role of aldosterone in left ventricular hypertrophy in hypertension[J].AJH,2006,19,13-18.
  • 5[3]Devereux RB,Palmieri V,Sharpe N,et al.Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based anti-hypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension:the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial[J].Circulation,2001,104:1248-1254.
  • 6[4]Klingbeil AU,Schneider M,Martus P,et al.A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension[J].Am J Med,2003,115:41-46.
  • 7[5]Arsalan S,karl T.Extracellular matrix remodeling in hypertensive heart disease[J].JACC,2006,48:1-2.
  • 8[6]Rubattu S,Bigatti G,Evangelista A,et al.Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension[J].JACC,2006,48,499-505.
  • 9[7]Taniguchi I,Kawai M,Date T,et al.Effects of spironolactone during an angiotensin Ⅱ receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy[J].Circ J,2006,70:995-1000.
  • 10[8]Krauser DG,Devereux RB.Ventricular hypertrophy and hypertension:Prognostic elements and implication for management[J].Herz,2006,31:305-316.

共引文献61

同被引文献218

引证文献16

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部